This $3,000,000 firm fixed-price contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Adjuvax LLC, a small disadvantaged, minority-owned business. The contract supports Small Business Innovation Research (SBIR) Topic 130, which focuses on discovering and down-selecting vaccine adjuvants for infectious and immune-mediated diseases. This work is intended to strengthen the role of small businesses in meeting federal research and development needs and advancing public health technology. The contract is set aside for total small business participation and represents a Phase II SBIR program action. Adjuvax LLC has previously received multiple SBIR contracts from NIAID totaling $4,200,000 for vaccine and adjuvant research.
Generated 3/1/25, 10:07 AM